Cargando…
The price, efficacy, and safety of within-class targeted anticancer medicines between domestic and imported drugs in China: a comparative analysis
BACKGROUND: Affordability to novel anticancer drugs has become a major health issue in China. It is encouraging to note that China initiated its drug regulatory reform and national price negotiation policies since 2015. As a growing number of domestic within-class targeted anticancer drugs are appro...
Autores principales: | Luo, Xingxian, Du, Xin, Huang, Lin, Guo, Qixiang, Tan, Ruijie, Zhou, Yue, Li, Zhuangqi, Xue, Xuecai, Li, Taifeng, Le, Kaidi, Qian, Feng, Chow, Shein-Chung, Yang, Yue |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918802/ https://www.ncbi.nlm.nih.gov/pubmed/36785854 http://dx.doi.org/10.1016/j.lanwpc.2022.100670 |
Ejemplares similares
-
Clinical Benefit, Price, and Uptake for Cancer Biosimilars vs Reference Drugs in China: A Systematic Review and Meta-Analysis
por: Luo, Xingxian, et al.
Publicado: (2023) -
Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022
por: Luo, Xingxian, et al.
Publicado: (2023) -
Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China
por: Zhang, Yichen, et al.
Publicado: (2022) -
Hospital Contracts and Prices: VI. Domestic
Publicado: (1910) -
Quantitative Methods for Traditional Chinese Medicine Development
por: Chow, Shein-Chung
Publicado: (2015)